Tysabri and Progressive Multifocal Leukoencephalopathy: What Massachusetts Clinicians Should Know

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a patient on Tysabri is concerned about progressive multifocal leukoencephalopathy (PML), understanding the risk factors and monitoring guidelines is essential. This concern builds on decades of pharmacovigilance research that has shaped current safety protocols. This page reviews the labeling, risk stratification, and clinical questions relevant to Massachusetts prescribers.

Tysabri and PML: Clinical Overview and Risk Factors

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. This section reviews the clinical presentation and diagnosis of PML, the pharmacology of Tysabri, mechanistic pathways linking the drug to PML, and risk considerations including warning adequacy, attorney-related factors for affected patients, and the timeline between exposure and harm. PML is a demyelinating disease of the central nervous system that typically occurs in immunocompromised individuals. It is caused by reactivation of the JC virus, which infects oligodendrocytes and leads to progressive neurological deficits. Common presenting symptoms include cognitive impairment, motor weakness, gait disturbance, visual deficits, and speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a monoclonal antibody that binds to alpha-4 integrin on leukocytes, inhibiting their migration across the blood-brain barrier. This mechanism reduces inflammatory activity in MS but also impairs immune surveillance in the central nervous system. The FDA Adverse Event Reporting System (FAERS) lists fatigue, MS relapse, headache, gait disturbance, and balance disorder among the most frequently reported adverse events for Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). However, the most serious risk is PML, which is highlighted in a boxed warning. Tysabri's inhibition of leukocyte trafficking into the brain reduces the normal immune monitoring that controls JC virus replication. In patients who are seropositive for anti-JCV antibodies, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to PML. Three established risk factors are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy.

Adequacy of Warnings and Legal Implications for Massachusetts Patients

The prescribing information for Tysabri includes a boxed warning that explicitly states the drug increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning advises healthcare professionals to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such indication. Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure informed risk-benefit decisions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients and providers fully understand the magnitude of risk, particularly regarding the cumulative effect of treatment duration and prior immunosuppressant use. For patients in Massachusetts who have developed PML after Tysabri treatment, legal considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Massachusetts, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury reasonably should have been discovered. Given that PML symptoms may develop gradually and diagnosis can be delayed, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused the harm. Affected individuals should consult with an attorney experienced in pharmaceutical litigation to assess their specific timeline and legal options. Documentation of treatment dates, symptom onset, and diagnosis is critical. PML typically occurs after prolonged Tysabri exposure, with risk increasing significantly beyond two years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The latency period from JC virus reactivation to clinical symptoms can range from weeks to months. Once symptoms appear, neurological deterioration can be rapid. Early detection through MRI and CSF analysis is essential, but even with prompt diagnosis, outcomes are often poor. The boxed warning emphasizes that Tysabri should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients and providers must remain vigilant throughout the treatment course.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury reasonably should have been discovered. For PML, which may develop gradually, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused the harm. It is crucial to consult an attorney promptly to preserve your rights.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should discuss these factors with their healthcare provider before and during treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.